Synopsis A novel clinical trial demonstrated that stent insertion into the pancreatic head was an independent risk factor for hyperamylasemia after endoscopic retrograde cholangiopancreatography (ERCP), while stent insertion up to the pancreatic body or tail reduced the risk of post-ERCP hyperamylasemia and may reduce the risk of pancreatitis (PEP). This week's ' JOurnal Watch ' discusses a clinical trial from World journal of gastroenterology, “ Pancreatic stents for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis should be inserted up to the pancreatic body or tail ”. June 2018.
Authors : Sugimoto M; Takagi T; Suzuki R; Konno N; Asama H; Sato Y; Irie H; Watanabe K; Nakamura J; Kikuchi H; Waragai Y. Key Takeaways Stent insertion up to the pancreatic body or tail reduced the risk of post-ERCP hyperamylasemia and may reduce the risk of pancreatitis…
